News
Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...
Stocktwits on MSN43m
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its ...
The stock has been in free fall since safety issues derailed a gene therapy analysts had expected to achieve blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback